GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline PLC isn't letting the fact that it doesn’t have a PD-1/L1 inhibitor get its immuno-oncology R&D efforts down. Instead, the company is focusing immuno-oncology research on next-generation checkpoint modulators, including the OX40 agonist antibody GSK3174998 and first-in-class ICOS agonist antibody GSK3359609, the company said during an R&D day in New York City Nov. 3.
You may also be interested in...
Walmsley Takes On Oncology: Can GSK Become A Power Player?
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
A Biopharma A-List Lineup Aims To Tackle Complex Manufacturing At Resilience
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm
Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.
Need a specific report? 1000+ reports available
Buy Reports